SV2017005601A - Formulaciones farmacéuticas que contienen tenofovir y emtricitabina - Google Patents

Formulaciones farmacéuticas que contienen tenofovir y emtricitabina

Info

Publication number
SV2017005601A
SV2017005601A SV2017005601A SV2017005601A SV2017005601A SV 2017005601 A SV2017005601 A SV 2017005601A SV 2017005601 A SV2017005601 A SV 2017005601A SV 2017005601 A SV2017005601 A SV 2017005601A SV 2017005601 A SV2017005601 A SV 2017005601A
Authority
SV
El Salvador
Prior art keywords
emtricitabine
pharmaceutical formulations
formulations containing
containing tenofovir
tenofovir
Prior art date
Application number
SV2017005601A
Other languages
English (en)
Inventor
Joanna M Koziara
Scott Mccallister
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2017005601(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SV2017005601A publication Critical patent/SV2017005601A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN PROPORCIONA UNA FORMA DE DOSIFICACIÓN ORAL SÓLIDA QUE COMPRENDE ALAFENAMIDA DE TENOFOVIR O UNA SAL FARNACÉUTICAMENTE ACEPTABLE DE LA MISMA, Y EMTRICITABINA O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LA MISMA
SV2017005601A 2015-06-30 2017-12-21 Formulaciones farmacéuticas que contienen tenofovir y emtricitabina SV2017005601A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562187113P 2015-06-30 2015-06-30
US201662298373P 2016-02-22 2016-02-22
US201662301429P 2016-02-29 2016-02-29
US201662317286P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
SV2017005601A true SV2017005601A (es) 2018-05-04

Family

ID=56418608

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005601A SV2017005601A (es) 2015-06-30 2017-12-21 Formulaciones farmacéuticas que contienen tenofovir y emtricitabina

Country Status (26)

Country Link
US (2) US20170000807A1 (es)
EP (5) EP3607939B1 (es)
JP (3) JP6667556B2 (es)
KR (2) KR102313668B1 (es)
CN (1) CN107847450A (es)
AU (3) AU2016287500B2 (es)
BR (1) BR112017027843A2 (es)
CA (1) CA2990210C (es)
CL (1) CL2017003320A1 (es)
CO (1) CO2017013293A2 (es)
CU (1) CU20170168A7 (es)
DO (1) DOP2017000306A (es)
EA (1) EA201792592A1 (es)
EC (1) ECSP17084331A (es)
ES (4) ES2925246T3 (es)
HK (1) HK1248547A1 (es)
IL (1) IL256364A (es)
MA (1) MA50541A (es)
MX (1) MX2017016806A (es)
PE (1) PE20180411A1 (es)
PH (1) PH12017502431A1 (es)
PL (4) PL4070787T3 (es)
PT (4) PT4070788T (es)
SI (4) SI4070787T1 (es)
SV (1) SV2017005601A (es)
WO (1) WO2017004244A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
ES2892123T3 (es) 2014-12-26 2022-02-02 Univ Emory Derivados antivíricos de N4-hidroxicitidina
TWI737647B (zh) 2015-11-09 2021-09-01 美商基利科學股份有限公司 用於治療人類免疫缺乏病毒之治療組合物
BR112019016935A2 (pt) 2017-02-17 2020-04-07 Eidos Therapeutics Inc processos para preparação de ag-10, seus intermediários e sais dos mesmos
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
WO2018175325A1 (en) * 2017-03-20 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv post-exposure prophylaxis
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
GB2581936B (en) 2017-12-07 2021-02-10 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
AU2019321583A1 (en) 2018-08-17 2021-01-21 Eidos Therapeutics, Inc. Formulations of AG10
CN111096954B (zh) * 2018-10-29 2022-09-16 江苏豪森药业集团有限公司 一种用于抗病毒感染的药物组合物及制备方法
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) * 2019-12-31 2020-03-27 常州恒邦药业有限公司 一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) * 2020-02-19 2021-05-21 台灣森本生物科技開發股份有限公司 含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
CN117338733B (zh) * 2023-10-12 2024-05-28 杭州和泽坤元药业有限公司 一种富马酸替诺福韦二吡呋酯片及其制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4651264B2 (ja) 2000-07-21 2011-03-16 ギリアード サイエンシーズ， インコーポレイテッド ホスホネートヌクレオチドアナログのプロドラッグならびにこれを選択および作製するための方法。
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US20040224917A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
AP3250A (en) 2009-02-06 2015-05-31 Gilead Sciences Inc Tablets for combination therapy
AU2012296622C1 (en) 2011-08-16 2017-02-16 Gilead Sciences, Inc. Tenofovir alafenamide hemifumarate
MD20140091A2 (ro) * 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
EA201690146A1 (ru) * 2013-08-14 2016-07-29 Ратиофарм Гмбх Лекарственное средство, содержащее фармацевтическую комбинацию долутегравира, эмтрицитабина и тенофовира
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (es) * 2014-06-20 2018-06-23

Also Published As

Publication number Publication date
CL2017003320A1 (es) 2018-07-13
EP3607939A1 (en) 2020-02-12
CA2990210C (en) 2021-01-12
ES2945896T3 (es) 2023-07-10
AU2019210558B2 (en) 2021-04-22
PL3316868T3 (pl) 2020-10-19
ES2925246T3 (es) 2022-10-14
PL4070788T3 (pl) 2023-07-10
AU2019210558A1 (en) 2019-08-15
DOP2017000306A (es) 2018-01-15
JP2021185188A (ja) 2021-12-09
HK1248547A1 (zh) 2018-10-19
KR102313668B1 (ko) 2021-10-19
WO2017004244A1 (en) 2017-01-05
MA50541A (fr) 2021-04-07
CN107847450A (zh) 2018-03-27
AU2016287500B2 (en) 2019-05-02
PE20180411A1 (es) 2018-03-01
PL3607939T3 (pl) 2022-11-07
ES2945345T3 (es) 2023-06-30
KR20200067937A (ko) 2020-06-12
EP4070787B1 (en) 2023-03-01
CA2990210A1 (en) 2017-01-05
PT4070788T (pt) 2023-06-06
US20170000807A1 (en) 2017-01-05
AU2021202009A1 (en) 2021-04-29
EA201792592A1 (ru) 2018-06-29
JP2018519297A (ja) 2018-07-19
US20180177734A1 (en) 2018-06-28
JP2020079304A (ja) 2020-05-28
EP4070788B1 (en) 2023-03-22
AU2021202009B2 (en) 2023-04-13
ES2786549T3 (es) 2020-10-13
EP4233846A2 (en) 2023-08-30
EP3316868A1 (en) 2018-05-09
ECSP17084331A (es) 2018-01-31
EP3316868B1 (en) 2020-02-19
MX2017016806A (es) 2018-05-07
PT3316868T (pt) 2020-04-21
PL4070787T3 (pl) 2023-07-24
AU2016287500A1 (en) 2018-01-18
EP3607939B1 (en) 2022-06-01
PH12017502431A1 (en) 2018-07-02
EP4233846A3 (en) 2023-10-04
PT4070787T (pt) 2023-05-22
EP4070787A1 (en) 2022-10-12
PT3607939T (pt) 2022-09-12
IL256364A (en) 2018-02-28
SI4070787T1 (sl) 2023-07-31
SI4070788T1 (sl) 2023-06-30
KR102121329B1 (ko) 2020-06-17
SI3607939T1 (sl) 2022-10-28
CU20170168A7 (es) 2018-07-05
KR20180021134A (ko) 2018-02-28
SI3316868T1 (sl) 2020-04-30
BR112017027843A2 (pt) 2018-09-04
EP4070788A1 (en) 2022-10-12
CO2017013293A2 (es) 2018-05-31
JP6978534B2 (ja) 2021-12-08
JP6667556B2 (ja) 2020-03-18

Similar Documents

Publication Publication Date Title
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
IL258464A (en) Pharmaceutical compositions for oral administration of peptide drugs
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
MX2017016802A (es) Formulaciones farmaceuticas.
HUP1700253A1 (hu) Szilárd orális gyógyszerkészítmények
IL264880A (en) Preparations for oral administration of active substances
MA55015A (fr) Formulations pharmaceutiques
GB2591396B (en) Pharmaceutical suspension for oral dosage
PT3326619T (pt) Composições farmacêuticas orais sólidas compreendendo tenofovir e emtricitabina
HUE062682T2 (hu) Ibuprofén tartalmú orális gyógyszerészeti készítmény
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين
CY1123966T1 (el) Διαδικασια για την παρασκευη νατριουχου εποπροστενολης ενισχυμενης σταθεροτητας
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
MA41643A (fr) Formulations pharmaceutiques d'inhibiteur de la tyrosine kinase de bruton
EA201790387A1 (ru) Фармацевтическая композиция для лечения острой зубной боли или боли в челюсти